PANDORA Doctoral Network PhD Position (DC4): Complement Dysregulation in Age-Related Macular Degeneration

PANDORA Doctoral Network PhD Position (DC4): Complement Dysregulation in Age-Related Macular Degeneration

Quick Decision

This doctoral project asks why immune cells persist beneath the retina in age-related macular degeneration (AMD), and whether abnormal complement activity changes their interaction with retinal pigment epithelium (RPE). The distinctive combination is human donor tissue, genetically defined iPSC-derived cell models and functional immune experiments, supported by an established retinal-inflammation team. It is most relevant to experimental cell biologists or immunologists who want to connect mechanism with disease models; it is not primarily a computational PhD.

Assessment: Strong but verify fit. The advertised employment lasts 36 months, with approximately €2,800 gross monthly salary plus mobility and, where eligible, family allowance. The saved institute vacancy page gives 30 November 2026, 18:00 Europe/Paris (1 December 2026, 01:00 Beijing time). The earlier recruitment notice recorded 23:59 on the same Paris date; the time conflict remains unresolved and should be confirmed with recruitment. The institute page states February 2027 as the start month, while the earlier notice specifies 1 February 2027; confirm the exact day. Nationality is unrestricted, but the France mobility rule and absence of a prior doctorate are hard conditions. Exact allowance amounts, net pay and the feasibility of the full experimental programme within three years remain important unknowns. The useful first step is to check the mobility calendar and prepare a one-page letter linking one completed experimental project to a specific DC4 question. Official vacancy, MSCA rules. Current application status has not been checked.

Research Problem and Doctoral Work

What Is Unsolved and Why It Matters

The healthy subretinal compartment normally restricts immune-cell accumulation. AMD involves persistent mononuclear phagocytes, including microglia and monocyte-derived macrophages. The unresolved point here is how complement dysregulation changes the survival, clearance and activity of these cells alongside RPE. The advert describes previous CFH 402H-related clearance findings, but the proposed experiments must distinguish complement-dependent effects from other genetic effects rather than treating every risk-associated phenotype as complement causality. Vacancy.

PANDORA is grant 101312030, coordinated by the University of Tübingen, with Sorbonne as a participant. Its network runs from October 2026 to September 2030 and combines complement biology, disease modelling and therapeutic development. Those network dates do not extend the individual 36-month contract automatically. Commission grant record.

Work, Methods, and Potential Outputs

The vacancy lists four connected tasks: official posting.

1. Use multiplexed immunohistochemistry on post-mortem retinal sections from AMD donors and age-matched controls to map classical, lectin and alternative pathway components, activation products, regulators (CFH and FHR1–5) and receptors. Whole-slide/confocal imaging and quantitative image analysis will relate their locations to microglia, monocyte-derived macrophages, RPE, photoreceptors and drusen.
2. Use the laboratory’s defined co-culture system with control and chromosome 1 (Chr1)-risk iPSC-derived RPE, microglia and monocyte-derived macrophages to study the haplotype’s effects and cell interactions. FHR1–5-depleted human plasma and purified complement factors will probe the role of plasma-derived FHR1–5.
3. Combine single-cell and bulk RNA sequencing with proteomics to assess microglia/macrophage polarisation, interaction with immunosuppressive RPE, inflammatory pathways and immune functions in healthy and AMD settings.
4. Test whether anti-C5 and anti-C3 complement inhibitors can restore immune balance in the models; this remains an experimental question, not a claim of clinical benefit.

The advertised techniques/training also include primary human monocyte isolation and differentiation, human plasma and purified complement-factor work, flow cytometry, qPCR, Western blot, ELISA/multiplex cytokine assays, and functional assays of phagocytosis, migration, survival and clearance. A listed technique is not necessarily a separately assigned doctoral work package.

A credible thesis would connect tissue-level observations, cell interactions and functional evidence while accounting for donor variability, model-batch variation, cell identity and genetic-background confounding. Molecular changes need a clear functional interpretation; a list of differentially expressed genes alone cannot establish mechanism. These are evidence-quality questions rather than additional admission conditions. Donor availability, ethics, model readiness and core-facility capacity need confirmation against the three-year timetable.

The therapeutic frontier makes this work relevant but demanding: The retained EMA Syfovre record reports refusal of EU authorisation after the 2024 review. Slower geographic-atrophy lesion growth did not establish sufficiently meaningful patient benefit relative to risk. Thus, reducing complement activity or inflammation in a dish cannot be described as restoring human vision. The project's value lies in clarifying mechanism and response heterogeneity, including potentially informative negative results. EMA assessment.

School, Programme and Field Context

The recruiting organisation is Sorbonne Université, Medicine Faculty; daily research is at Institut de la Vision, 17 rue Moreau, Paris 75012. The notice explicitly specifies enrolment in Sorbonne ED394, leading to a PhD. The institute is a joint Sorbonne/Inserm/CNRS research unit, with an ophthalmic clinical-research environment through FOReSIGHT and the 15-20 hospital. These relationships support translational contact; they do not establish a joint degree, clinical-practice licence, or guaranteed access to patients. The legal employing entity and payroll terms should be stated in the offer contract. Institute at Sorbonne, vacancy.

ED394, P2T, covers physiology, pathophysiology and therapeutics, including immunology, inflammation, ageing and vision. Its official page describes about 250 doctoral researchers and accreditation by Sorbonne. Partner institutes are part of the environment, not additional confirmed awarders. General admission requires a Master or equivalent, research aptitude, supervisor/host-unit agreement and the university admission decision; formal registration remains necessary after recruitment. Exact ED394 training hours, committee milestones and thesis publication requirements were not retrieved and should be obtained from the school. ED394, doctoral admission.

For a bounded reputation comparison, the ranking publisher labels Sorbonne 55th overall in ARWU 2026 and 76–100 in GRAS 2026 Biological Sciences, Human Biological Sciences and Clinical Medicine. These are broad institutional/subject signals, not an ophthalmology, AMD or supervision ranking. The stronger project-level evidence is the relevant team, disease models and papers below. The institute describes a multidisciplinary doctoral environment with engineers, postdocs and clinical proximity, but its account is institutional self-description rather than an independently verified completion or placement study. ShanghaiRanking, doctoral environment.

Supervisor and Lab Assessment

Research Directions and Recent Papers

Dr Florian Sennlaub is the advertised supervisor and an institute research director/team head. The team studies inflammatory neuronal degeneration and vascular remodelling across AMD, diabetic retinopathy and uveitis; its methods link phagocyte identity, genetic risk and tissue injury. A current publication list includes 2025 work, while the following three closely read 2023–2024 papers were selected for direct AMD relevance. Publication activity supports scientific continuity, but does not establish mentoring quality or available supervision time. Profile, team.

• Mathis et al., JCI 2024, DRD2 activation and choroidal neovascularization. Experimental models and a retrospective insurance cohort connect dopaminergic signalling to neovascular disease. The importance for DC4 is the discipline of joining mechanism with human observations; some effects occur independently of phagocyte accumulation, warning against equating all AMD endpoints. The human component is observational, not a randomized therapeutic trial. Assessment used the PubMed abstract, affiliations and detailed figure legends. Paper record.
• Roubeix et al., Journal of Neuroinflammation 2024, splenic monocytes. Single-cell analysis and perturbations distinguish a splenic monocyte contribution to retinal inflammation in mouse models, with an associated human plasma observation. This informs cell-origin controls and the combination of transcriptomic identity with functional experiments. It does not prove that the same intervention benefits AMD patients. Open paper.
• Augustin et al., Journal of Neuroinflammation 2023, melanophages and hyperreflective foci. Human donor tissue and experimental models identify pigmented phagocytes and investigate CD47-dependent pigment transfer. This is directly relevant to identifying cells correctly in donor retina and connecting histology with disease-associated imaging. Post-mortem associations and model interventions do not establish a clinically effective treatment. Open paper.

Resources and Supervision Boundaries

The institute lists cell culture, biological resources, biochemistry, imaging and cell/tissue phenotyping platforms. Its 2025 report describes MACSima multiplex imaging development, demonstrating engineering support while also documenting validation, time and data burdens. The report does not assume DC4 will use that instrument, have priority access, or receive unlimited sequencing. The platform directory's sequencing entry describes Sanger capability; the vacancy's transcriptomics work does not establish an in-house high-throughput sequencer. Ask who performs each major assay and who pays. Platforms, MACSima report.

PANDORA workshops, complementary skills, conference support and academic/industrial secondments are advertised. Actual destinations, durations, daily mentor, meeting cadence, authorship practices and the balance between tissue, culture and analysis are not public commitments yet. The network is a useful collaboration structure, but individual access and responsibilities require an explicit plan.

Funding, Application, and Living Cost

Employment and Paris Spending

The notice offers 36 months, full-time, 35 hours/week, approximately €2,800/month gross before tax and employee social-security deductions, with mobility and eligible family allowance additional. Their amounts and payroll treatment are not specified. EU institutional contribution figures or generic MSCA unit costs must not replace this advertised gross figure or be presented as take-home salary. Request a written breakdown of base gross, allowances, employee deductions and illustrative net pay. Sorbonne confirms income-tax withholding and that employment income may be taxable; individual circumstances and treaties need proper checking. Vacancy, MSCA funding categories, Sorbonne taxation.

The university's 2026/27 doctoral enrolment fee is €398/year, and doctoral enrolment is excluded from differentiated non-EU fees. CVEC rules also require attention; the project's reimbursement policy and the applicable 2027 amount are unconfirmed. No funding beyond month 36 is promised. Ask how thesis completion and enrolment are supported if essential experiments run late. Fees.

As an indicative city comparison, SKEMA's July 2026 guide gives a €1,200–€1,500 monthly mid-range student budget, shared rooms around €500–€900, and private studios €800–€1,400. These are general planning ranges, not a housing quotation or a guaranteed expenditure ceiling. Its private-rental setup estimate of €1,500–€3,000 illustrates the additional cash needed at arrival. A single employed doctoral researcher may find the salary workable with controlled housing costs, but the evidence does not support a precise savings claim from gross salary. Family costs need a separate budget. Paris budget guide.

University housing is not assured. Sorbonne's reserved CIUP arrangements have specific mobility conditions and limited places; its CROUS text specifically discusses non-salaried doctoral students. A salaried DC4 candidate cannot assume eligibility or allocation. The Health faculty lists an age-limited ALJT young-worker/student route and private housing examples, but these are leads, not confirmed rooms for February 2027. Verify accommodation eligibility, commute and first-payroll timing with the doctoral college. Housing conditions, faculty practical information.

Eligibility and Submission

Applicants may be of any nationality, including Chinese citizens in principle. They must not hold a doctorate at recruitment and must not have lived or conducted their main activity in France for more than 12 months during the preceding 36 months. Compulsory national service and refugee-status procedures are excluded as specified in the notice. The reference point is recruitment, not the submission deadline; borderline travel/residence cases require the recruiting team's decision. A Chinese Master is subject to equivalent-degree/admission assessment, not automatic recognition. MSCA rules, Sorbonne admission.

For a non-EU researcher, the government's researcher-talent route requires an appropriate qualification, research purpose and an approved hosting agreement; applicants abroad use consular procedures. This is a viable administrative framework, not an individual visa guarantee or a clinical qualification. Confirm the institution's hosting-document process and secondment mobility arrangements. Government guidance.

Prepare a CV, a one-page cover letter, and contact details of one or two academic referees. The saved institute vacancy page instructs applicants to complete its online application form and attach the CV and cover letter as PDFs. Recruitment follows the open, transparent and merit-based principles of the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers. florian.sennlaub@inserm.fr remains the named contact. The earlier recruitment notice listed email submission; whether email alone is accepted should be confirmed rather than assumed. Submit by 30 November 2026, 18:00 Europe/Paris (Beijing 1 December, 01:00), while preserving the unresolved 23:59 time in the earlier listing. Current application status has not been checked. The notice describes online interviews for shortlisted candidates. No French is required; excellent spoken/written English is essential. It does not require initial reference letters or a long research proposal in place of the stated package. Official vacancy pointer.

Applicant Fit, Preparation, and Career Implications

Required: a relevant Master or equivalent, solid cellular/molecular biology and/or immunology, excellent English, motivation for retinal degeneration/neuroinflammation, and capacity for independent and team work. Preferred: practical cell culture, ideally primary immune or iPSC-derived cells; flow cytometry; immunostaining/image analysis; innate immunity/macrophage/microglia/complement background; and interest/basic experience in omics. The complete methods list is a training programme, not proof that every technique must already be mastered.

Suggested preparation: use one completed project to show controls, replication, troubleshooting and quantitative interpretation. Explain how previous research distinguishes genetic-background associations from model variability, and what makes a functional interpretation credible. Basic reproducible R/Python analysis and familiarity with single-cell QC are useful additions, not newly imposed prerequisites. Purely computational applicants without experimental preparation, or clinical applicants seeking clinical practice rather than laboratory research, face a larger mismatch with the advertised work.

Possible skill-based routes include retinal/immunology postdoctoral research, cell-model or assay development, biomarker research and translational biotechnology. France Biotech's 2026 survey reports active hiring intentions alongside financing pressure: these are broad HealthTech signals, not AMD-specific vacancies or this lab's graduate placements. The portable value is rigorous human-cell experimentation, imaging and immune/omics analysis; the degree does not guarantee a permanent academic job, industry salary or French clinical licence. Actual alumni destinations and the industrial secondment's work content would be more informative than sector slogans. Industry survey.

Next Actions and Questions to Verify

Before Applying

• Calculate the France residence/main-activity history against the likely recruitment date; ask about any borderline exclusions.
• Confirm the relevant Master equivalence process and whether the stated February 2027 start permits degree-completion and immigration timing.
• Complete the official form and required short package before 30 November 2026, 18:00 Europe/Paris (Beijing 1 December, 01:00); confirm any email alternative and connect experimental evidence to a precise DC4 question.

At Interview

• Which donor/model resources and ethics approvals are ready, and how is the strength of the resulting evidence assessed?
• Which work package has priority if tissue collection or differentiation is delayed? Who owns the omics analysis and validation?
• Who is the daily mentor, how often will supervision occur, and what are the secondment hosts, timing and objectives?
• What are ED394's training, monitoring and thesis requirements, and how are publications and authorship planned?

Before Accepting an Offer

• Obtain written gross/allowance/net illustrations, fee/CVEC responsibility and the exact employing entity.
• Confirm housing eligibility, hosting-agreement/visa support, first payment timing and secondment travel/accommodation coverage.
• Ask about funded completion beyond 36 months if necessary, and request recent alumni destinations or contact with current doctoral researchers.

Evidence and Sources

Scientific and paper evidence dates from 17 October 2026. Recruitment evidence dated 18 October 2026 (Asia/Shanghai) covers the institute's full vacancy and its online form, with 30 November at 18:00 Europe/Paris. The earlier notice instead gives 23:59 and email submission; the date of any wording change is unknown. Other sources retain their stated dates and scope. Mathis was assessed through the PubMed abstract and figure legends; the two Journal of Neuroinflammation papers are represented by their open article texts. Rankings, budgets and surveys retain their stated years and limits.

Project, institution and training

• Institut de la Vision: PANDORA doctoral vacancy
• EURAXESS listing for PANDORA DC4
• Institut de la Vision website
• Institut website listed in the EURAXESS contact block
• European Commission: PANDORA grant 101312030
• MSCA Doctoral Networks: candidate and funding rules
• Sorbonne ED394 P2T doctoral school
• Sorbonne: doctoral admission
• Sorbonne 2026/27 enrolment fees
• ShanghaiRanking: Sorbonne overall and subject results
• Institut 2025: doctoral training environment
• Sorbonne: Institut de la Vision research unit

Supervisor, papers and research resources

• Florian Sennlaub: official researcher profile
• Inflammation and immunology in retinal diseases: team
• Mathis et al. 2024: DRD2 activation and choroidal neovascularization
• Roubeix et al. 2024: Splenic monocytes drive pathogenic subretinal inflammation in AMD
• Augustin et al. 2023: Melanophages give rise to hyperreflective foci in AMD
• EMA: Syfovre refusal and benefit-risk reasoning
• Institut de la Vision technology platforms
• Institut 2025 annual report: MACSima imaging development

Paris, taxation, immigration and careers

• Sorbonne: institutional housing routes and limits
• Sorbonne Health: Paris practical accommodation information
• SKEMA July 2026: Paris student budget guide
• France Biotech: HealthTech 2026 industry survey release
• Sorbonne: income tax and payroll withholding
• French government: researcher talent residence route